GlassScriptPhysician profile
Scott A Lisse
NPI 1346245818
$4,270.99
in general payments reported to CMS, 2019-2025
36 companies · $270 in 2025
The $270 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,696 · 2020: $602 · 2021: $456 · 2022: $444 · 2023: $485 · 2024: $317 · 2025: $270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,073.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $778.67 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amarin Pharma, INC. | $382.41 | 2019-2022 | |
| Astellas Pharma US INC | $328.11 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $219.79 | 2019-2021 | |
| Abbott Laboratories | $198.77 | 2019-2023 | Freestyle Libre 3 |
| Janssen Pharmaceuticals, INC | $196.26 | 2019-2022 | |
| Lilly USA, LLC | $180.19 | 2019-2023 | Mounjaro |
| Inspire Medical Systems, INC. | $157.05 | 2023-2025 | Inspire |
| Abbvie INC. | $152.81 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $146.13 | 2019-2021 | |
| Gilead Sciences, INC. | $138.09 | 2019-2023 | |
| Glaxosmithkline, LLC. | $137.15 | 2019-2025 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.99 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $131.72 | 2019-2023 | Hetlioz |
| Astrazeneca Pharmaceuticals LP | $121.55 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $108.32 | 2019-2025 | |
| Dexcom, INC. | $86.54 | 2024-2025 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $83.09 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $60.36 | 2019-2020 | |
| Medtronic Vascular, INC. | $55.58 | 2020 | |
| Amgen INC. | $54.35 | 2019-2023 | Repatha, Otezla |
| Allergan, INC. | $49.44 | 2019-2020 | |
| Sanofi Pasteur INC. | $42.82 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.54 | 2019-2022 | |
| Genentech USA, INC. | $30.50 | 2019-2021 | |
| Shire North American Group INC | $29.73 | 2019 | |
| Emd Serono, INC. | $28.23 | 2023 | Serostim |
| Abiomed | $27.63 | 2024 | Impella |
| Ironshore Pharmaceuticals INC. | $26.69 | 2019 | |
| Titan Spine, LLC | $24.22 | 2019 | |
| Idorsia Pharmaceuticals US INC | $24.18 | 2023 | Quviviq |
| Amneal Pharmaceuticals LLC | $23.30 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $20.98 | 2021 | |
| Metuchen Pharmaceuticals | $20.43 | 2019 | |
| Assertio Therapeutics, INC. | $19.01 | 2020 | |
| Jazz Pharmaceuticals INC. | $11.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Lisse listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.